Adrafinil
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Adrafinil (2-benzhydrylsulfinyl-N-hydroxyacetamide) is a synthetic eugeroic of the benzhydrylsulfinylacetamide class. It is a prodrug of modafinil — it converts to modafinil in the liver, the form that actually acts in the brain. Modafinil blocks dopamine reuptake, raising dopamine levels and promoting wakefulness.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Adrafinil was identified in 1974 in France and launched commercially as Olmifon in 1985, prescribed for narcolepsy and age-related vigilance decline.[2] Modafinil proved clinically superior — it worked directly without the liver conversion step — and the manufacturer voluntarily withdrew Olmifon in 2011.[3] It now circulates as an unregulated supplement in several jurisdictions.[4]
Subjective effects include sustained wakefulness, cognitive clarity, mood elevation, and increased motivation. The experience is one of quiet alertness — a gradual, clean arousal without the jittery push or euphoria of amphetamine-class stimulants.[5] Insomnia, headache, nausea, and mild anxiety are common unsought effects.[6]
Dependence liability is minimal and acute toxicity is low.[5][7] The dominant chronic concern is the liver — adrafinil requires extra hepatic processing compared to modafinil, and one case of persistent involuntary facial movements after chronic use has been documented.[8] No dedicated clinical trials exist for adrafinil; the evidence base rests almost entirely on modafinil research and assumed equivalence after conversion.[9]
History[edit]
Discovery
Adrafinil was identified in 1974 by researchers at Laboratoire Louis Lafon in France during systematic study of benzhydryl sulfoxide compounds.[2] Modafinil was recognized as adrafinil's primary active metabolite two years later.[10] Michel Jouvet, the neurologist who discovered REM sleep, began prescribing adrafinil to narcoleptic patients around 1977 but switched to modafinil directly by 1983 after inconsistent results.[2]
Clinical and commercial history
Adrafinil launched in France on 19 September 1985 as Olmifon, indicated for narcolepsy and vigilance deficits in the elderly.[2][3] Modafinil received French registration in 1992 and proved superior — it worked directly without the liver conversion step. The manufacturer voluntarily discontinued Olmifon in September 2011, citing an unfavorable risk–benefit ratio.[3][2]
Modern era
After discontinuation, adrafinil re-emerged in the nootropic supplement market, particularly in jurisdictions where it remains unregulated.[4] It has been confirmed in US products marketed as dietary supplements.[4] The compound now occupies a regulatory paradox: a discontinued pharmaceutical sold over the counter while its active metabolite is controlled or prescription-only in most of the developed world.[11]
The class name "eugeroic" — from the Greek eu (good) and gregor (wakening) — was coined for this new category of wakefulness-promoting agents, of which adrafinil is a founding member.[12] Both adrafinil and modafinil were banned in competitive sport by the World Anti-Doping Agency in 2004 under S6 (Stimulants), prohibited in-competition only.[13][14]
Chemistry[edit]
Structural class
Adrafinil belongs to the benzhydrylsulfinylacetamide family — compounds built around a diphenylmethane core linked to a sulfinyl group. What distinguishes it from its active metabolite modafinil is a hydroxamic acid group where modafinil carries a simpler acetamide. The liver cleaves this group during metabolism, yielding modafinil and an inactive byproduct.[6][15]
Molecular identity
| Molecular formula | C₁₅H₁₅NO₃S |
| Molecular weight | 289.35 g/mol |
The molecule connects a diphenylmethane group through a sulfinyl bridge (S=O) to an N-hydroxyacetamide chain.[16][17] Both adrafinil and modafinil emerged from systematic study of benzhydryl sulfoxide compounds at Laboratoire Louis Lafon in the 1970s.[2]
Pharmacology[edit]
Mechanism of action
Adrafinil is a prodrug — its effects require liver conversion to modafinil before it acts in the brain.[6][15] Whether it has direct pharmacological activity of its own remains unknown.[12][18] Modafinil blocks the DAT, raising dopamine levels in arousal circuits and promoting wakefulness.[1]
Unlike amphetamine-class stimulants, modafinil blocks dopamine reuptake without triggering direct dopamine release.[5][19] This distinction explains its lower reinforcement potential — blockade produces a gentler, slower rise in dopamine than release does. It also activates orexin, histamine, and norepinephrine wakefulness circuits.[6][20][5]
Pharmacokinetics
The liver converts adrafinil to modafinil (active) and modafinilic acid (inactive).[6][15] Modafinil reaches peak blood levels 2–4 hours after oral dosing and has a half-life of approximately 12–15 hours.[21] For adrafinil, onset is slower and peak modafinil levels may be lower, because the conversion step takes time and is incomplete.
Neuroscience[edit]
Where it acts
Modafinil — the active form of adrafinil — promotes wakefulness through dopaminergic circuits connecting the midbrain to the prefrontal cortex.[19] It selectively engages cortical arousal pathways rather than the brain's reward circuits. This selectivity explains why it produces alertness without the strong euphoria or abuse liability of amphetamines.[19]
Why it matters
Modafinil's profile demonstrates that wakefulness and reward can be pharmacologically separated. Dopamine rises in reward regions of the brain, but not enough in magnitude or speed to generate strong pleasure or compulsive use.[19][5] The result is motivation and alertness without the pull toward repeated use that defines amphetamines.
Whether adrafinil has pharmacological activity independent of its conversion to modafinil remains unknown — it has been classified as an alpha-1 adrenergic agonist, but no binding data exist to confirm this.[12] One case of persistent involuntary facial movements after chronic use[8] raises the possibility of dopaminergic sensitization, but no systematic follow-up exists. The long-term neural effects of chronic use are uncharacterized.
Subjective Effects[edit]
Adrafinil's effects unfold gradually as the liver converts it to modafinil. The experience is quiet, sustained alertness — a clean wakefulness that builds over an hour or two rather than arriving abruptly. There is no jittery push and no pronounced euphoria.
The experience is qualitatively identical to Modafinil but typically slower to arrive and potentially less intense due to the conversion step.[5][19] Compared to amphetamine-class stimulants, adrafinil produces notably less euphoria and anxiety at equivalent wake-promoting doses. Individual variation is substantial, shaped by liver activity, sleep debt, and prior stimulant tolerance.
Effect Grid
Sustained wakefulness for 4–6 hours with clear focus enhancement and motivation. Cognitive clarity is the dominant quality — tasks feel easier to initiate and maintain. Memory updating shows the most consistent improvement based on modafinil meta-analytic data (SMD = 0.28). Thought acceleration may be subtly present. The experience resembles a productive, unremarkable state of heightened alertness rather than overt stimulation.
Mild appetite suppression is typical. Headache occurs in a substantial minority (up to 34% in modafinil clinical trials). Nausea is possible. Slight elevation in heart rate may be noticed by sensitive individuals. Dehydration sensation is occasionally reported.
Total duration is approximately 6–10 hours. Sleep disruption is likely if dosed in the afternoon. The slow onset means planning around the 1–2 hour conversion delay is important for timing peak effects with demanding work.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Appetite suppression · Pupil dilation · Nausea · Dry mouth · Heart rate perception changes · Restlessness · Dizziness · Dehydration sensation · Vomiting
Heart rate perception changes · Restlessness · Dizziness · Dehydration sensation · Vomiting
Information processing enhancement · Thought organization
Timeline
Gradual awareness of increasing alertness as hepatic conversion to modafinil begins. Effects are subtle — drowsiness lifts slowly rather than stimulation arriving. Most users notice little during this phase under rested conditions.
Progressive sharpening of focus and wakefulness as modafinil plasma levels rise. Mental clarity increases noticeably. The transition is smooth — there is no abrupt gear-shift characteristic of direct-acting stimulants.
Sustained plateau of wakefulness and cognitive clarity. Focus enhancement and motivation are most prominent. The quality is characteristically clean — alertness without agitation or euphoria.
Gradual reduction in stimulation without a sharp crash. Wakefulness fades smoothly as modafinil plasma levels decline. Concentration returns to near-baseline.
Residual mild alertness or difficulty initiating sleep. Lingering appetite suppression is occasionally reported. Some users experience subtle cognitive clarity persisting below the threshold of active stimulation.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- 10.5 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- modafinil · armodafinil · benzhydryl class nootropics
Toxicity
Acute toxicity is low.[7] Common adverse effects — derived from modafinil clinical data — include headache, nausea, nervousness, insomnia, diarrhea, dry mouth, and elevated blood pressure and heart rate.[6]
Heart and circulation
Elevated heart rate and blood pressure are documented at clinical doses.[6] Cardiovascular risk is lower than with cocaine, desipramine, and bupropion at equivalent doses in animal models.[22]
Liver
Modafinil is rated an unlikely cause of clinically apparent liver injury. In a US study of 899 drug-induced liver injury cases, none were attributed to modafinil, and liver enzyme elevations above three times normal occurred in under 1% of patients in safety trials.[9]
Adrafinil requires additional liver processing compared to taking modafinil directly. No primary literature documents adrafinil-specific liver injury, but liver enzyme monitoring is recommended for regular use.safety citation needed
Movement disorders
One documented case describes persistent involuntary facial movements — uncontrolled repetitive movements of the mouth and jaw — following chronic adrafinil use.[8] The movements did not resolve after four months off the drug and required treatment with a dopamine-depleting medication. Neurologically vulnerable individuals, including the elderly, appear at higher risk.citation needed
Skin reactions
Rare severe skin reactions — including blistering rashes and a reaction involving fever, skin peeling, and organ involvement — have been reported with modafinil, more commonly in children.[9]
Psychological risks
Anxiety and nervousness are documented at higher doses.[6] A systematic review found no predominance of adverse mood changes when modafinil was used for cognitive enhancement in healthy individuals.[23] Caution is warranted for anyone with a history of psychosis or mania, given dopaminergic stimulation.inferred
Tolerance and dependence
Tolerance develops with prolonged use, driven by dopamine receptor changes from sustained DAT occupancy.[1] Physical dependence is rare — few confirmed cases appear in the published literature.[5] Cross-tolerance is confirmed with modafinil and armodafinil.
Psychological reliance is possible, but adrafinil does not sustain robust self-administration in animal models.[5] Lower addiction risk compared to amphetamines reflects slower dopamine elevation, absence of direct dopamine release, and selective arousal without strong reward signaling.[5][19] Fatigue rebound effect after stopping chronic use has been reported; no severe withdrawal has been documented.citation needed
Drug interactions
The most critical interaction involves hormonal contraceptives. Modafinil activates a liver enzyme (CYP3A4) that accelerates the breakdown of hormonal contraceptives, reducing their effectiveness.[24] Alternative or backup contraception is required during adrafinil use and for at least one month after stopping.
Modafinil also inhibits a second liver enzyme (CYP2C19), slowing the breakdown of certain medications and raising their blood levels — including phenytoin, diazepam, omeprazole, propranolol, and some antidepressants.[25][21] Combining with other stimulants (amphetamine, cocaine, methylphenidate) adds cardiovascular strain through overlapping dopamine effects.[26] No published data exist for combinations with monoamine oxidase inhibitors, but theoretical concern for increased toxicity exists.safety citation needed
Contraindications
Liver impairment is the most significant contraindication specific to adrafinil — impaired liver function may reduce conversion to modafinil while increasing exposure to the parent compound.[21]
Known allergy to modafinil or armodafinil is an absolute contraindication, as adrafinil converts directly to modafinil.
Use in children is contraindicated due to elevated risk of severe skin reactions.[9]
History of psychosis or mania is a relative contraindication due to dopaminergic stimulation.inferred
Heart conditions warrant caution due to potential blood pressure and heart rate elevation.[6]
Hormonal contraceptive use requires alternative or backup contraception.[24]
Harm Reduction[edit]
Forms & Identification
Adrafinil circulates as a white crystalline powder, sold in capsules or loose form through online supplement retailers. It is a discontinued pharmaceutical — all available product comes from third-party chemical suppliers without pharmaceutical-grade quality control. Purity varies significantly between vendors, and mislabeling or substitution with other benzhydryl compounds is possible.
Third-party laboratory testing provides the most reliable verification of identity and purity.
Guidelines
- Start with the lowest effective dose and allow a full 2 hours before assessing effects — the prodrug conversion creates a slow onset that does not reflect final intensity
- Use only in the morning or early afternoon to avoid insomnia
- Avoid daily use — chronic dosing increases hepatic burden compared to modafinil
- Request liver enzyme testing before beginning a course of regular use and periodically thereafter
- Stay hydrated and maintain regular meals, as appetite suppression may mask hunger
- Test purchased material through a third-party laboratory when possible
Set & Setting
Adrafinil's delayed onset (1–2 hours) and long duration make timing critical. Morning dosing avoids interference with sleep. The prodrug conversion creates a deceptively slow start — first-time users sometimes redose prematurely, believing the initial dose was ineffective, and experience excessive stimulation hours later.
A calm, productive environment suits the compound's quiet alertness profile.
Aftercare & integration. Adrafinil's long duration means residual stimulation can persist into the evening. Prioritize sleep recovery: dim lighting, avoid screens, and allow a 2–3 hour wind-down before attempting sleep. Eat a full meal if appetite was suppressed during the day. Avoid caffeine in the afternoon and evening following use.
After regular use, fatigue rebound effect is common for several days. Allow natural sleep-wake cycles to re-establish before resuming any stimulant. If use was motivated by chronic fatigue or cognitive difficulty, consider whether the underlying cause warrants medical evaluation rather than continued self-medication.
Recovery & Support
Physical dependence on adrafinil is rare, but psychological reliance on wakefulness-promoting agents can develop — particularly when use masks underlying sleep disorders, depression, or chronic fatigue. If adrafinil use has become routine to function normally, this pattern warrants honest assessment.
A healthcare provider can evaluate whether an underlying condition is driving the need for cognitive enhancement. Gradual tapering rather than abrupt cessation minimizes fatigue rebound. Support resources include sleep medicine clinics and, where use has become compulsive, addiction support services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Adrafinil emergencies are rare but recognizable.
Signs that require immediate help:
- Chest pain, rapid or irregular heartbeat
- Severe allergic reaction: skin rash, swelling of the face or throat, difficulty breathing
- Uncontrollable involuntary movements, especially of the face or jaw
- Seizure or loss of consciousness
- Severe anxiety or paranoid thinking that does not respond to reassurance
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Keep the person calm, seated, and in a quiet environment
- 3. Do not induce vomiting
- 4. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher: name the substance (adrafinil), the amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Adrafinil occupies an unusual position in drug law: a discontinued pharmaceutical whose active metabolite (modafinil) is controlled or prescription-only in most countries, while adrafinil itself remains unscheduled in several major markets.[4][11]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled, unregulated | Not FDA-approved; not a DEA-controlled substance; legal to possess and privately import[4] |
| United Kingdom | Not specifically scheduled | Falls under Psychoactive Substances Act 2016, restricting commercial supply but not personal possession[27] |
| France | Discontinued pharmaceutical | Olmifon marketed 1985–2011; voluntarily withdrawn by Cephalon[2][3] |
| Canada | Unregulated | Legal as research chemical; can be purchased and privately imported[27] |
| Australia | Prescription required | Not freely available over the counter[27] |
| Germany | Available as research chemical | Not approved as pharmaceutical; no prescription required[28] |
| New Zealand | Prescription required | Regulated as prescription medicine[27] |
| WADA (sport) | Prohibited in-competition | S6 Stimulants category since 2004; metabolizes to modafinil (also prohibited)[13][14] |
Legal status varies by jurisdiction and can change without notice. In the United States, the Federal Analogue Act could theoretically apply to adrafinil as a structural analog of modafinil (Schedule IV), but enforcement under this provision has not been documented.citation needed This information is not legal advice — verify current local regulations before purchasing or possessing adrafinil.
references
- [1] ^abcVolkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. — JAMA doi:10.1001/jama.2009.351
- [2]
- [3]
- [4]
- [5]
- [6]